STOCK TITAN

Evogene - EVGN STOCK NEWS

Welcome to our dedicated page for Evogene news (Ticker: EVGN), a resource for investors and traders seeking the latest updates and insights on Evogene stock.

Overview

Evogene (EVGN) is a pioneering computational biology company that leverages big data, artificial intelligence, and deep scientific insights to revolutionize the development of life-science-based products. Operating at the convergence of biotechnology and computational analytics, the company focuses on creating breakthrough solutions in agriculture, human health, and industrial applications. With its roots in advanced plant genomics research, Evogene integrates proprietary tech-engines and innovative predictive platforms to enhance seed traits and crop productivity.

Core Business Model and Technologies

At the heart of Evogene’s operations is its unique technology infrastructure composed of three distinct tech-engines: MicroBoost AI, ChemPass AI, and GeneRator AI. These platforms allow the company to systematically accelerate the discovery and development of novel products by targeting and optimizing key components such as microbes, small molecules, and genetic elements. This multi-engine approach not only reduces development time and costs but also increases the probability of success through sophisticated computational predictive biology.

Market Position and Strategic Collaborations

Evogene operates in the high-stakes arena of life sciences, where precision and innovation drive competitive advantage. The company addresses challenges in agricultural productivity by improving seed traits related to yield enhancement and stress tolerance. Its strategic collaborations with world-leading agricultural firms underscore its role as an unbiased, research-driven innovator in the sector. These partnerships facilitate the development of advanced ag-biological products, which include bio-inoculants and seed treatments that are designed to address both biotic and abiotic stresses in crops such as corn, soybean, wheat, and rice.

Diverse Subsidiary Operations

Evogene’s business model is diversified through its subsidiaries, each specializing in a niche area within the life sciences:

  • Lavie Bio Ltd. focuses on developing microbiome-based ag-biologicals and innovative bio-stimulant products using the MicroBoost AI tech-engine, enhancing crop vigor and stress tolerance.
  • Biomica Ltd. is dedicated to creating human microbiome-based therapeutics, harnessing the capabilities of its computational platforms to address complex medical challenges.
  • AgPlenus Ltd. utilizes ChemPass AI to design next-generation agricultural chemicals, supporting sustainable and effective crop protection measures.
  • Casterra Ag Ltd. commercializes elite castor seed varieties for biofuel and biopolymer production, making use of GeneRator AI to optimize plant genomics for industrial applications.

Technology-Driven Innovation and Operational Excellence

Evogene’s approach is deeply rooted in an advanced understanding of computational predictive biology. By leveraging its proprietary platforms and extensive datasets, the company is able to pinpoint genetic elements and microbial candidates that directly contribute to improved agricultural outputs. Its innovative use of artificial intelligence and big data analytics has allowed for rapid prototyping of solutions, which are then validated through extensive field trials and strategic partnerships. This methodical integration of technology into the research and development process affirms its commitment to reducing time-to-market while ensuring product efficacy and sustainability.

Competitive Landscape and Industry Significance

Within the rapidly evolving fields of computational biology and ag-biotechnology, Evogene distinguishes itself by combining deep domain expertise with technology-driven innovation. Unlike conventional approaches that rely on traditional trial-and-error methods, Evogene’s integrated strategy is designed to systematically inform product development, thereby minimizing risks while maximizing innovative output. Its successful collaborations with established industry players position Evogene as an authoritative resource in product design and predictive biology.

Key Industry Terminology and Concepts

The company’s operations are underpinned by several industry-specific terminologies that resonate with experts in the field:

  • Computational predictive biology: Utilizing algorithms and large data sets to model and predict biological outcomes.
  • Proprietary tech-engines: Engineered platforms such as MicroBoost AI, ChemPass AI, and GeneRator AI that incorporate multidisciplinary expertise.
  • Plant genomics: The scientific study of plants at the molecular level, which is critical to enhancing desirable seed traits.
  • Ag-biologicals and ag-chemicals: Products designed to improve crop resilience and productivity, often replacing traditional chemical inputs.

Conclusion

Evogene stands as an exemplar of how cutting-edge technology can drive advancements in the life-science sector. By integrating deep scientific research with sophisticated AI-driven platforms, the company not only improves agricultural outputs but also paves the way for innovative solutions in human therapeutics and industrial applications. Its diverse portfolio, strategic collaborations, and focus on continuous innovation have firmly established its reputation as a dynamic, forward-thinking entity in the competitive landscape of computational biology.

Rhea-AI Summary

Evogene Ltd. (NASDAQ: EVGN) reported its financial results for Q4 and full year 2021, showing an operating loss of $31 million, up from $24.8 million in 2020. The company maintains a solid cash position of approximately $54 million, aiding its subsidiaries in product development. Key achievements include Biomica's clearance for a phase I immuno-oncology study and Canonic's commercial sales of cannabis products. Looking ahead, Evogene targets 2022 milestones such as launching new products and expanding R&D activities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.75%
Tags
-
Rhea-AI Summary

Evogene Ltd. (NASDAQ: EVGN) announced its participation in the upcoming World Agri-Tech Innovation Summit on March 22-23, 2022, in San Francisco. This summit has established itself as a pivotal event for the global agtech ecosystem, bringing together growers, agribusiness leaders, technology pioneers, and investors. Key executives from Evogene, including CEO Ofer Haviv and other senior management from its subsidiaries, will be present to explore partnerships and insights. Evogene leverages cutting-edge computational biology to innovate in various life-science industries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.54%
Tags
conferences
-
Rhea-AI Summary

Evogene Ltd. (NASDAQ: EVGN) announced its participation in the 34th Annual ROTH Conference in Dana Point, California, from March 13-15, 2022. CEO Ofer Haviv will host a live fireside chat on March 15 at 12pm PT, along with one-on-one meetings with investors. The conference includes various presentations and panels, attracting institutional investors and analysts. Evogene's innovative technologies, such as MicroBoost AI and GeneRator AI, are focused on life-science product development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.92%
Tags
conferences
Rhea-AI Summary

Canonic Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN), announced the appointment of Professor Itamar Grotto to its Board of Directors. Grotto, formerly of the Israeli Ministry of Health, brings extensive expertise in medical cannabis reform. His role aims to bolster Canonic's mission of developing medical cannabis products targeting specific medical indications. Grotto believes in the potential of Canonic to enhance patient care and expressed eagerness to contribute to the company's growth. CEO Arnon Heyman welcomed Grotto, emphasizing his valuable experience for advancing Canonic's strategic goals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
management
-
Rhea-AI Summary

Evogene Ltd. (NASDAQ: EVGN) is set to release its financial results for the full year and fourth quarter of 2021 on March 10, 2022. Following the announcement, management will host a conference call at 09:00 AM Eastern time to discuss these results. The call can be accessed via phone or live webcast on the company's website. Evogene leverages advanced computational biology technologies to enhance life-science product development across various sectors including therapeutics and ag-chemicals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.25%
Tags
-
Rhea-AI Summary

Evogene Ltd. (NASDAQ-GM: EVGN) will present an overview at the Aegis Capital Corp. Virtual Conference from February 23 to 25, 2022. The presentation is set for February 25 at 9:00 AM EST. Interested participants can access the presentation upon request to Aegis or view the slide deck on Evogene's website. Evogene is a computational biology company aiming to innovate product development in life sciences, using its Computational Predictive Biology platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
conferences
Rhea-AI Summary

Canonic Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN), announced the shipment of its first batch of cannabis varieties to Portugal after receiving export approval from the Israeli Ministry of Health and Ministry of Agriculture. This shipment is part of Canonic's preparations for a planned commercial launch in Europe in 2023, focusing on developing medical cannabis products using its Computational Predictive Biology platform. The shipped cannabis varieties will undergo lab testing and regulatory examination to comply with European regulations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.75%
Tags
none
-
Rhea-AI Summary

Evogene Ltd. (NASDAQ: EVGN) announced its participation in the Edison Group's Global Healthcare Open House Event from January 25-27, 2022. The event will take place virtually, and Evogene's presentation will be available on demand starting at 7 AM ET on January 27. Attendees can also register for 1x1 meetings with the company. Evogene utilizes its Computational Predictive Biology platform to advance product pipelines in various life-science sectors, including human health and agriculture.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.71%
Tags
conferences
-
Rhea-AI Summary

Canonic Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN), announced positive outcomes in pre-clinical studies focused on inflammation and pain relief involving specific cannabis varieties. Conducted by Hadassah Medical Center and Migal - Galilee Research Institute, these studies support Canonic's Precise product line aimed at medical cannabis. The company has filed a patent application for these cannabis varieties. The first products are projected for release in Israel in 2023, with plans to expand into Europe, as the medical cannabis market is expected to exceed €1 billion in Europe this year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.1%
Tags
Rhea-AI Summary

Biomica, a subsidiary of Evogene (NASDAQ: EVGN), received clearance from the Israeli Ministry of Health to proceed with a Phase I clinical trial for its drug candidate BMC-128. This trial will involve patients with Non-Small Cell Lung Cancer, Melanoma, or Renal Cell Carcinoma, evaluating BMC-128 in combination with Bristol Myers Squibb's Opdivo® (an anti-PD-1 therapy). The study aims to assess the safety and tolerability of this microbiome-based therapy at Rambam Health Care Campus.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.37%
Tags
none

FAQ

What is the current stock price of Evogene (EVGN)?

The current stock price of Evogene (EVGN) is $1.12 as of April 22, 2025.

What is the market cap of Evogene (EVGN)?

The market cap of Evogene (EVGN) is approximately 6.8M.

What is Evogene's core business?

Evogene is a computational biology company that uses artificial intelligence and big data to develop innovative life-science products, including advanced solutions for agriculture and human health.

What proprietary technologies does Evogene use?

The company has developed three unique tech-engines—MicroBoost AI, ChemPass AI, and GeneRator AI—which are used to optimize the discovery and development of products based on microbes, small molecules, and genetic elements.

How does Evogene contribute to agricultural productivity?

Through its deep understanding of plant genomics and strategic partnerships, Evogene enhances seed traits, develops bio-inoculant products, and optimizes crop resistance to biotic and abiotic stresses.

What are Evogene's main market segments?

Evogene operates in multiple segments including agriculture, human therapeutics, and industrial applications, leveraging its AI-driven platforms to address diverse market needs.

Who are Evogene's key subsidiaries?

Evogene's portfolio includes Lavie Bio for ag-biologicals, Biomica for human microbiome-based therapeutics, AgPlenus for ag-chemicals, and Casterra Ag for advanced castor seed cultivation.

How does Evogene's technology reduce development time and cost?

By integrating computational predictive biology with big data analytics, Evogene’s platforms streamline product discovery and optimization, significantly cutting down on both time and cost during development.

What differentiates Evogene from other biotech companies?

Evogene’s unique integration of AI-driven tech-engines with deep scientific expertise in plant genomics and life sciences sets it apart, enabling more accurate predictions and faster development cycles.

How does Evogene maintain its competitive edge in the industry?

Through strategic collaborations, continuous innovation, and a diversified portfolio of subsidiaries, Evogene positions itself as an authoritative and trusted partner in the development of life-science products.
Evogene

Nasdaq:EVGN

EVGN Rankings

EVGN Stock Data

6.76M
6.59M
1.56%
7.68%
0.51%
Biotechnology
Healthcare
Link
Israel
Rehovot